E
Camp4 Therapeutics Corporation CAMP
$1.65 $0.063.77% NASDAQ
Recommendation
Prev Close
$1.71
Volume
42,549
Avg Vol (90D)
256,002
Market Cap
$34.48M
Dividend & Yield
--
52-Week Range
$1.31 - $12.30
P/E (TTM)
--
EPS (TTM)
-$26.20
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Camp4 Reports Q2 Revenue Beats Estimates
8/14/2025 - Fool.com Headlines
Camp4 Therapeutics reports Q2 EPS (62c), consensus (67c)
8/14/2025 - The Fly
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
8/14/2025 - Globe Newswire
Here's Why Camp4 Therapeutics (NASDAQ:CAMP) Must Use Its Cash Wisely
7/2/2025 - Simply Wall St
Sequans Appoints Jason W. Cohenour to Board of Directors
6/30/2025 - Newsfile Corp. - News Releases
Camp4 Therapeutics (CAMP) Gains Analyst Support with Promising Treatment CAMP Stock News
5/27/2025 - GuruFocus
Wedbush Sees Bright Future for Camp4 Therapeutics (CAMP) with New Coverage CAMP Stock News
5/27/2025 - GuruFocus
Camp4 Therapeutics initiated with bullish view at Wedbush, here's why
5/27/2025 - The Fly
Camp4 Therapeutics initiated with bullish view at Wedbush
5/27/2025 - The Fly
Piper Sandler Keeps Their Buy Rating on CAMP4 Therapeutics Corporation (CAMP)
5/19/2025 - TipRanks Financial Blog
CAMP4 Therapeutics (CAMP) Highlights Promising Data from Gene Therapy Trials CAMP Stock News
5/16/2025 - GuruFocus
Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders
5/16/2025 - TipRanks Financial Blog
Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders
5/16/2025 - The Fly
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
5/16/2025 - Globe Newswire
Camp4 Therapeutics Corp Reports Q1 2025 Net Loss of $12.4 Million, Cash Reserves at $49.3 Million
5/15/2025 - GuruFocus
William Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)
5/14/2025 - TipRanks Financial Blog
Camp4 Therapeutics reports Q1 EPS (62c), consensus (70c)
5/13/2025 - The Fly
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
5/13/2025 - Globe Newswire
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
4/28/2025 - Globe Newswire
CAMP4 Therapeutics Advances RNA-Based Therapeutics
4/1/2025 - TipRanks Financial Blog
Camp4 Therapeutics Corp Reports 2024 Financial Results with $51. ...
3/29/2025 - GuruFocus
William Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)
3/28/2025 - TipRanks Financial Blog
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
3/27/2025 - Globe Newswire
Camp4 Therapeutics appoints Williams, Stewart to board of directors
3/18/2025 - The Fly
Income Statement
Total Revenue (TTM)
$3.01M
EBITDA (TTM)
-$51.99M
EBIT (TTM)
-$53.68M
Net Income (TTM)
-$51.78M
Balance Sheet
Total Assets (Q)
$51.28M
Total Debt (Q)
$7.22M
Total Liabilities (Q)
$11.29M
Book Value Per Share (Q)
$1.98
Cash Flow
Cash from Operations (TTM)
-$45.61M
Cash from Investing (TTM)
-$542.00K
Cash from Financing (TTM)
$72.60M
Net Change in Cash (TTM)
$26.45M
Filings
Filing Date
Thursday, August 14, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Oct 6 and 10 (est)
Price History
Loading...
Beta
--
7-Day Total Return
19.57%
30-Day Total Return
7.14%
60-Day Total Return
-17.09%
90-Day Total Return
-17.50%
Year to Date Total Return
-66.53%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Jun 20, 2025 - $1.31
52-week High
Oct 14, 2024 - $12.30
Valuation
Market Cap
$34.48M - Nano Cap
Enterprise Value
$2.64M
Price/Sales (TTM)
11.47
Price/Book (Q)
0.86
Dividends and Shares
Shares Outstanding
20.16
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.camp4tx.com
Phone Number
617-651-8867
Address
One Kendall Square
3rd Floor - Building 1400 West
Cambridge, MA 02139
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product... more
NASDAQ 08/22/2025 2:55PM Eastern Quotes delayed